X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (85) 85
respiratory system (81) 81
humans (78) 78
pulmonary hypertension (73) 73
female (66) 66
male (62) 62
middle aged (56) 56
abridged index medicus (54) 54
adult (49) 49
hypertension, pulmonary - physiopathology (37) 37
cardiac & cardiovascular systems (36) 36
survival (36) 36
hypertension, pulmonary - drug therapy (34) 34
aged (33) 33
critical care medicine (29) 29
transplantation (29) 29
pulmonary arterial hypertension (25) 25
treatment outcome (24) 24
follow-up studies (23) 23
care and treatment (22) 22
diagnosis (22) 22
drug therapy (22) 22
adolescent (21) 21
prognosis (21) 21
therapy (21) 21
double-blind method (20) 20
hypertension (20) 20
research (20) 20
disease (19) 19
pulmonary/respiratory (19) 19
surgery (19) 19
analysis (18) 18
hypertension, pulmonary - mortality (18) 18
antihypertensive agents - therapeutic use (17) 17
risk factors (17) 17
bosentan (16) 16
lung transplantation (15) 15
medical colleges (15) 15
registries (15) 15
time factors (14) 14
endothelin receptor antagonists (13) 13
prospective studies (13) 13
usage (13) 13
hypertension, pulmonary - diagnosis (12) 12
retrospective studies (12) 12
familial primary pulmonary hypertension (11) 11
hemodynamics (11) 11
mortality (11) 11
survival rate (11) 11
transplantation of organs, tissues, etc (11) 11
united states - epidemiology (11) 11
antihypertensive agents - administration & dosage (10) 10
clinical trials (10) 10
continuous intravenous epoprostenol (10) 10
endothelin (10) 10
lungs (10) 10
medicine, general & internal (10) 10
prostacyclin (10) 10
ambrisentan (9) 9
cardiology and cardiovascular medicine (9) 9
dose-response relationship, drug (9) 9
double-blind (9) 9
hypertension, pulmonary - etiology (9) 9
hypertension, pulmonary - therapy (9) 9
registry (9) 9
sulfonamides - therapeutic use (9) 9
arterial-hypertension (8) 8
dosage and administration (8) 8
drug therapy, combination (8) 8
epoprostenol - administration & dosage (8) 8
exercise (8) 8
heart (8) 8
heart-failure (8) 8
hemodynamics - physiology (8) 8
patient outcomes (8) 8
pulmonary (8) 8
pulmonary arteries (8) 8
sildenafil (8) 8
sitaxsentan (8) 8
antihypertensive agents - adverse effects (7) 7
brain natriuretic peptide (7) 7
disease progression (7) 7
exercise test (7) 7
exercise tolerance (7) 7
health aspects (7) 7
hemodynamics - drug effects (7) 7
hypertension, pulmonary - epidemiology (7) 7
management (7) 7
outcomes (7) 7
prostacyclin analog (7) 7
respiratory agents (7) 7
reveal (7) 7
walking - physiology (7) 7
young adult (7) 7
administration, oral (6) 6
cardiovascular (6) 6
combination therapy (6) 6
complications (6) 6
controlled-trial (6) 6
disease management (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 08/2015, Volume 373, Issue 9, pp. 834 - 844
Patients with previously untreated pulmonary arterial hypertension who were randomly assigned to combination therapy with ambrisentan and tadalafil had a... 
INHALED ILOPROST | SURVIVAL | TRIAL | DIAGNOSIS | MEDICINE, GENERAL & INTERNAL | EPOPROSTENOL | COMBINATION THERAPY | HEART-FAILURE | DOUBLE-BLIND | BOSENTAN | Hypertension, Pulmonary - mortality | Double-Blind Method | Humans | Middle Aged | Risk Factors | Kaplan-Meier Estimate | Hypertension, Pulmonary - physiopathology | Male | Hospitalization | Disease Progression | Tadalafil | Phenylpropionates - therapeutic use | Peptide Fragments - blood | Adult | Female | Phenylpropionates - adverse effects | Aged | Hypertension, Pulmonary - drug therapy | Drug Therapy, Combination | Carbolines - therapeutic use | Carbolines - adverse effects | Natriuretic Peptide, Brain - blood | Pyridazines - adverse effects | Pyridazines - therapeutic use | Symptomatology | Care and treatment | Usage | Analysis | Clinical trials | Dosage and administration | Pulmonary hypertension | Ambrisentan | Hypertension | Edema | Brain natriuretic peptide | Headache | Functional morphology | Pulmonary arteries | Lung diseases | Drug therapy | Patients | Clinical outcomes | Index Medicus | Abridged Index Medicus | Drug side effects | Assaigs clínics de medicaments | Efectes secundaris dels medicaments | Hipertensió pulmonar | Drug testing | Life Sciences | Human health and pathology | Kardiologi | Clinical Medicine | Cardiac and Cardiovascular Systems | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2009, Volume 54, Issue 21, pp. 1971 - 1981
Journal Article
Annals of Internal Medicine, ISSN 0003-4819, 10/2008, Volume 149, Issue 8, pp. 521 - 530
Background: Oral sildenafil and intravenous epoprostenol have independently been shown to be effective in patients with pulmonary arterial hypertension.... 
INHALED ILOPROST | SURVIVAL | MEDICINE, GENERAL & INTERNAL | ORAL SILDENAFIL | EFFICACY | TREPROSTINIL | SAFETY | COMBINATION THERAPY | PROSTACYCLIN | BOSENTAN | Piperazines - administration & dosage | Injections, Intravenous | Humans | Middle Aged | Sulfones - adverse effects | Antihypertensive Agents - administration & dosage | Hypertension, Pulmonary - physiopathology | Male | Dyspepsia - chemically induced | Purines - administration & dosage | Hemodynamics - physiology | Walking - physiology | Sildenafil Citrate | Time Factors | Epoprostenol - adverse effects | Adult | Female | Hypertension, Pulmonary - drug therapy | Purines - adverse effects | Drug Therapy, Combination | Headache - chemically induced | Double-Blind Method | Administration, Oral | Piperazines - adverse effects | Antihypertensive Agents - adverse effects | Adolescent | Quality of Life | Aged | Vasodilator Agents - adverse effects | Hypertension, Pulmonary - etiology | Vasodilator Agents - administration & dosage | Epoprostenol - administration & dosage | Sulfones - administration & dosage | Complications and side effects | Epoprostenol | Dosage and administration | Sildenafil | Drug therapy, Combination | Research | Drug therapy | Pulmonary hypertension | Hypertension | Inhibitor drugs | Patients | Quality of life | Index Medicus | Abridged Index Medicus
Journal Article
Chest, ISSN 0012-3692, 09/2011, Volume 140, Issue 3, pp. 829 - 830
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 05/2006, Volume 47, Issue 10, pp. 2049 - 2056
Journal Article
Methodist DeBakey Cardiovascular Journal, ISSN 1947-6094, 2016, Volume 12, Issue 4 Suppl, pp. 10 - 13
Pulmonary hypertension (PH) is a complication and marker of disease severity in many parenchymal lung diseases. It also is a frequent complication of portal... 
parenchymal lung disease | pulmonary hypertension | Supplement | end-stage renal disease | COPD
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 08/2005, Volume 46, Issue 3, pp. 529 - 535
Journal Article
American Journal of Respiratory and Critical Care Medicine, ISSN 1073-449X, 12/2015, Volume 192, Issue 11, pp. 1345 - 1354
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 07/2017, Volume 76, Issue 7, pp. 1219 - 1227
Journal Article